Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...

Pfizer plans to slash over 200 jobs in Switzerland amid major restructuring for cost savings. Targets leaner ops by 2027, post-Covid revenue drop.

The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.

What a SpaceX IPO could mean for Tesla shareholders, Pfizer pursuing next weight-loss drug in Chinese labs, more news to ...

The Phase 3 "BASIS" trial data, showcased at the American Society of Hematology (ASH) annual meeting, showed significant promise. For patients with inhibitors—a subgroup historically difficult to ...

Pfizer shares managed to close the trading week with modest gains, but any investor relief is likely to be fleeting. Market attention is now fixed on a pivot ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

The Prudent Speculator is an investment newsletter that has been published monthly since 1977. Buckingham and his team run four value-stock portfolios. The flagship Prudent Speculator Portfolio has ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

Market analysts are pointing to substantial growth potential for Pfizer Inc. following a challenging period for the pharmaceutical giant. While many investor ...